What’s the Benefit of Taking the Oncotype DX Breast Cancer Assay?

What Will I Find out by Taking the Oncotype DX Breast Cancer Assay?

Oncotype DXThe Oncotype DX Breast Cancer Assay is one of the only four genomic tests for breast cancer. The results of this test have been validated with a prospective research.

Now your probably thinking, “That is great, but what in the world is an Oncotype DX Breast Cancer Assay and how can this test help me?”

The Oncotype DX Breast Cancer Assay was developed to determine the likelihood of  breast cancer recurrence. The use of the Oncotype DX score has now increased over time.

Find out from Surgical Oncologist Dr. Jennifer Manders how you can benefit from taking the Oncotype DX Breast Cancer Assay and finding out your DCIS Score results.

Transcript

Jennifer B. Manders:  There is a test called the Oncotype DX test which was developed for use in invasive breast cancer and this test helped to determine the likelihood of recurrence somewhere else in a woman’s body at 10 years after diagnosis if she was treated with tamoxifen alone and no chemotherapy. The use of Oncotype DX score has increased over time and we now have data for node positive patients.

We can use it in the setting of aromatase inhibitors which is a newer generation of estrogen modulation in the breast and in the body and we can also use it to determine the likelihood of benefit that a woman would receive from chemotherapy.  That test was then altered to look at its benefit in DCIS and so the DCIS recurrence score is actually a subset of genes that were originally used in the Oncotype DX score for invasive breast cancer.